peoplePerson
Matthew D. Galsky
Led trials that brought immunotherapy into bladder cancer and tested skipping cystectomy in responders.
Genitourinary oncologist who led IMvigor130 and studies of chemo-immunotherapy with bladder preservation in muscle-invasive disease.
Role
Director, Genitourinary Medical Oncology; Co-Director, Center of Excellence for Bladder Cancer
Specialisms
Bladder cancerImmunotherapyBladder preservation
Profiles
| Title | Journal | Year |
|---|---|---|
| Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130) | Lancet | 2020 |
Pages like this
not linked directly; found by shared links- TrialCheckMate 274
Shares Nivolumab, Bladder & urothelial cancer.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Atezolizumab, PD-L1, Nivolumab.
- IdeaImmunotherapy downstaging to transplant with a safe washout
Shares Atezolizumab, Nivolumab.
- TrialBEATcc / ENGOT-Cx10 / GOG-3030
Shares Atezolizumab, PD-L1.
- Key paperIwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack
Shares Atezolizumab, PD-L1, Nivolumab.
- TrialIMbrave150
Shares Atezolizumab, PD-L1.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
- PersonTasuku Honjo